Allarity Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
24 SCHOOL ST., 2ND FLOOR, BOSTON, MA, 02108
Mailing Address
24 SCHOOL ST., 2ND FLOOR, BOSTON, MA, 02108
Phone
401-426-4664
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 1, 2026 | View on SEC |
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 8-K Current report of material events | March 6, 2026 | View on SEC |
| 8-K Current report of material events | February 19, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 4, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 29, 2026 | View on SEC |
| 8-K Current report of material events | January 29, 2026 | View on SEC |
| 4 Insider stock transaction report | January 16, 2026 | View on SEC |
Annual Reports
10-K
March 30, 2026
- Proprietary DRP® technology improves clinical trial success by identifying patient-specific drug responses.
- Strategic pivot to focus 100% of research budget on lead candidate stenoparib.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.